A viral trick that restores memory: how a strategy borrowed from viruses could reverse cognitive decline
Viruses have spent millions of years evolving ways to hijack cells and sidestep stress responses. Researchers have now repurposed one of those viral tricks as a therapeutic tool, with surprising effects on cognitive decline in the aging brain.
When cells come under stress, whether from infection, heat, oxygen deprivation or accumulating proteins, they activate an emergency program known as the integrated stress response (ISR). That program puts a brake on protein production, shuts down non-essential processes and tries to keep the cell alive. In the short term, that is protective. In the long term, when the ISR stays chronically switched on as it does in neurodegenerative conditions, it turns destructive: synaptic plasticity declines, memory formation stalls and neurons lose their functional flexibility.
Viruses know this. Or rather, they have evolved to get around it. Some viruses produce proteins that block the ISR, freeing them to hijack the cell's protein-making machinery for their own replication. A study published in Science has stolen that strategy and rebuilt it for therapeutic purposes. Using viral ISR inhibitors as a blueprint, the researchers developed molecules capable of suppressing the chronically activated stress response in aging neurons.
Winning back memory in animal models
In mouse models of cognitive decline, ranging from age-related deterioration to Alzheimer's models, the treatment produced significant improvements in memory tasks. The researchers were able to partly restore the cognitive performance of old mice to levels reminiscent of younger animals. That finding is not entirely new: earlier work with ISR inhibitors such as ISRIB produced comparable results. What sets this study apart is its mechanistic precision. By taking viral strategies as a starting point, the researchers could intervene more precisely at specific nodes in the signaling chain.
The ISR pathway is an attractive therapeutic target because it is implicated in multiple neurodegenerative conditions at once. Chronic ISR activation has been observed in Alzheimer's disease, Parkinson's disease, frontotemporal dementia and even in normal aging. An intervention that breaks that chronic activation without disrupting the normal stress response could therefore have broad applications.
The risks of switching off stress
But that very breadth is also a concern. The integrated stress response exists for good reason: it protects cells against real damage. Any therapy that inhibits it needs to be extremely selective, or it risks increased susceptibility to infection, disrupted immune function or other side effects. The viral blueprint offers an advantage here: viruses are themselves under evolutionary pressure to be selective, because they depend on the host cell to reproduce. Whether that selectivity translates into safe applications in humans is a question for clinical trials that have yet to be set up.